Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMS-03305293 and Temozolomide in Relapsed Small Cell Lung Cancer
NCT06931626Phase 1Recruiting
- Sponsor
- Nerviano Medical Sciences
- Start
- Aug 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of itareparib in small cell lung cancer (SCLC), sponsored by Nerviano Medical Sciences. Primary endpoint: Number of Participants with Adverse Events. Started Aug 2025; status: recruiting.
02
Drugs
itareparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06931626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06931626.